• Eli Lilly and Co., of Indianapolis, and Bristol-Myers Squibb Co., of New York, said Erbitux (cetuximab) in combination with chemotherapy regimen Folfiri (irinotecan, 5-fluorouracil, leucovorin) is the first biologic treatment regimen in nearly a decade to receive FDA approval for newly diagnosed metastatic colorectal cancer.